Who is sponsoring NCT03572660?

NCT03572660 is sponsored by Barts & The London NHS Trust.

What drugs are being tested in NCT03572660?

Interventions in NCT03572660: Bone marrow derived mononuclear cells and G-CSF.

What condition does NCT03572660 study?

NCT03572660 studies Dilated Cardiomyopathy.

Is NCT03572660 still recruiting?

NCT03572660 is currently active, enrolled. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT03572660: DCM-Support

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM

Active, enrolled Phase 2 Last updated 6 April 2026

What this trial tests

Phase 2 trial testing Bone marrow derived mononuclear cells and G-CSF in Dilated Cardiomyopathy in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

24 December 2018

Primary endpoint
31 March 2030

31 March 2030

Quick facts

Lead sponsor	Barts & The London NHS Trust
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	24 December 2018
Primary completion	31 March 2030
Estimated completion	31 March 2030
Sites	1 location across United Kingdom

Drugs / interventions tested

Bone marrow derived mononuclear cells and G-CSF — full drug profile →

Conditions studied

Dilated Cardiomyopathy — all drugs for Dilated Cardiomyopathy →

Sponsor

Barts & The London NHS Trust — full company profile →

Who can join

Adults 18 to 85, any sex, with Dilated Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

DCM Support is recruiting patients with dilated cardiomyopathy and heart failure symptoms. The goal of this clinical trial is to examine whether treatment with a patient's own stem cells can improve their heart function and alleviate heart failure symptoms. * Stem cells will be collected from bone marrow in the patient's hip under local anaesthetic. * The stem cells will be infused into the arteries that supply blood to the heart under local anaesthetic. * A mini heart pump will be used to take the strain off the heart during the procedure. * The follow-up involves a phone call at 1 month and clinic visits at 3 and 12 months

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Locoregional delivery of stem cell-based therapies.
Ng NN, Thakor AS. · · 2020 · cited 24× · PMID 32522806 · DOI 10.1126/scitranslmed.aba4564
Human Stem Cells for Cardiac Disease Modeling and Preclinical and Clinical Applications-Are We on the Road to Success?
Correia CD, Ferreira A, Fernandes MT, Silva BM, et al · · 2023 · cited 22× · PMID 37443761 · DOI 10.3390/cells12131727
DCM Support: cell therapy and circulatory support for dilated cardiomyopathy patients with severe ventricular impairment.
Reid A, Hussain M, Veerapen J, Ramaseshan R, et al · · 2023 · cited 3× · PMID 37190883 · DOI 10.1002/ehf2.14393
Left Ventricular Unloading in Nonischemic Dilated Cardiomyopathy Improves Coronary Haemodynamic Reserve.
Fawaz S, Ramaseshan R, Khan S, Davies JR, et al · · 2025 · PMID 40145630 · DOI 10.1002/ccd.31514

Verify or expand the search:

Other recruiting trials for Dilated Cardiomyopathy

Currently open trials in the same condition.

NCT07241104 — A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy · Phase 1 · recruiting
NCT06250257 — Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age · Phase 3 · recruiting
NCT06730464 — Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy · recruiting
NCT06236022 — The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus · Phase 4 · recruiting
NCT05837143 — Myocardial Telomere Recapping Study for Dilated Cardiomyopathy · EARLY_PHASE1 · active not recruiting

Other Barts & The London NHS Trust trials

Trials by the same sponsor.

NCT05753085 — Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment · NA · withdrawn
NCT07047235 — Substrate Remodelling and Targeted Ablation in AF · NA · recruiting
NCT07076524 — MuScle WastIng and DysphaGia iN CriticAlly IlL Patients (SIGNAL) · recruiting
NCT06871215 — Inflammation and Infective Endocarditis · withdrawn
NCT06596486 — A Comparison of CoolStick With Ethyl Chloride for the Assessment of Light Touch · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03572660 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Barts & The London NHS Trust
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03572660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing